Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000177229 | SCV000229070 | uncertain significance | not provided | 2014-06-23 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000667198 | SCV000791616 | uncertain significance | GNE myopathy | 2017-05-19 | criteria provided, single submitter | clinical testing | |
NIHR Bioresource Rare Diseases, |
RCV000852136 | SCV000899760 | likely pathogenic | Thrombocytopenia | 2019-02-01 | criteria provided, single submitter | research | |
Labcorp Genetics |
RCV001296886 | SCV001485863 | uncertain significance | GNE myopathy; Sialuria | 2022-02-03 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with histidine, which is basic and polar, at codon 187 of the GNE protein (p.Tyr187His). This variant is present in population databases (rs794727505, gnomAD 0.006%). This missense change has been observed in individual(s) with clinical features of myopathy (PMID: 24796702, 28320138; Invitae). ClinVar contains an entry for this variant (Variation ID: 196410). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |